PeriodontitisNCT05680441
GCF Annexin-A1, Carbonic Anhydrase-1, and Elongation Factor-1 Gamma Levels in Periodontitis
An observational study of Periodontitis and Periodontal Inflammation, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).
Trial summary
The study aimed to investigate gingival crevicular fluid (GCF) levels of possible novel biomarkers Annexin-A1 (ANX A1), Carbonic anhydrase- 1 (CA I), and Elongation Factor-1 Gamma (EF1-Ɣ) in health along with different periodontal diseases. Read more about this study
- Who is it for?
- Ages 20 to 61 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontitis, Periodontal Inflammation
- What is being tested?
- Peirodontal clinical measurements and gingival crevicular fluid sampling
- Type of treatment
- Pill or oral medicine
- How many people
- 80 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2022to 16 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 61 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: A total of 80 systemically healthy and non-smoker individuals(39 males, 41 females) aged 20-61 years were consecutively included.
Who may be able to join
- Non-smokers with no history of smoking(determined by self-reporting)
- Individuals who had at least 20 teeth(exclude wisdom teeth)
Who cannot join
- Pregnant and lacting women
- Patients who under any medication including immunosuppressants, steroids, non-steroidal anti-inflammatory drugs, antibiotics, antiepileptic drugs, calcium channel blockers, beta,blockers, anticoagulants, hormonal contraceptives and nutritional supplements within 6 monthsi topical antiseptic solutions in the last 3 months.
- Patients with diagnosed medical illness such as diabetes mellitus, rheumatoid arthritis, cardiovascular diseases, immunological diseases.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Dokuz Eylul University, Faculty of Dentistry, Department of Periodontology
Izmir, 35340
About this study
Official title: Evaluation of Annexin-A1, Carbonic Anhydrase-1, and Elongation Factor-1 Gamma Levels in Periodontal Diseases
The study aimed to investigate gingival crevicular fluid (GCF) levels of possible novel biomarkers Annexin-A1 (ANX A1), Carbonic anhydrase- 1 (CA I), and Elongation Factor-1 Gamma (EF1-Ɣ) in health along with different periodontal diseases.
In total, 80 systemically healthy individuals were included in this study; 20 with periodontitis stage 3 grade B , 20 with periodontitis stage 3 grade C (P-Stage III/C), 19 with gingivitis, and 21 with clinically healthy periodontium. Probing depth, clinical attachment level, plaque index, and papillary bleeding index were recorded. GCF ANX A1, CA I and EF1-Ɣ levels were analyzed by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristics curve was used for estimating the under the curve.
Read the detailed description
Diagnosis of periodontal diseases and conditions was arranged according to the radiographic and clinical diagnostic criteria proposed by the 2017 World Workshop on Classifcation of Periodontal and Peri-implant Diseases and Conditions; 20 patients with Stage III Grade B generalized periodontitis , 20 patients with Stage III Grade C generalized periodontitis , 19 gingivitis patients and periodontally healthy volunteers were included in this study.
The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants. The measurements were performed using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA). All measurements were performed full mouth and at 4 sites (mesio-buccal, mid-buccal, distobuccal, and mid-lingual) for each tooth. Before clinical measurements, intra-examiner calibration was performed by measuring PPD and CAL values twice on five patients with one day interval resulting in intraclass correlation coefficients were 0.92 for PD and 0.90 for CAL.
GCF samples were taken from the buccal aspects of two nonadjacent interproximal sites in single-rooted teeth. In periodontitis groups, GCF was sampled from two deepest pockets of single-rooted teeth. Samples were collected from the sites with visible signs of inflammation in gingivitis group and without BOP in the healthy group. The selected areas were carefully cleared of supragingival plaque using sterile curettes, isolated with cotton rolls, and slightly air-dried to avoid contamination.
Standardized filter paper strips (PerioPaper, Proflow, Amityville, NY) were used for GCF sampling. Sterile paper strips were gently inserted into the gingival sulcus or pocket until mild resistance was felt and left there for 30 seconds. Mechanical irritation was avoided and strips visually contaminated with blood were discarded. A precalibrated electronic device measured the absorbed fluid volume (Periotron 8010, Oraflow, Amityville, NY). The readings were converted to an actual volume (microliter, μL) by reference to the standard curve. The paper strips were individually placed into a sterile polypropylene tube and stored at -80◦C for further analysis.
Annexin-A1 levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: 201-12-3158). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the Annexin-A1 kit were 0.20-20 ng/mL, sensitivity 0.2 ng/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.
Carbonic anhydrase 1 levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: SRB-T-88927). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the CA I kit were 3.12-200ng/mL, sensitivity <1.875ng/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.
EEF1G levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: 201-12-3732). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the EF1- Ɣ kit were 31.25-2000pg/mL, sensitivity <12.4pg/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.
Statistical analysis was performed using non-parametrical techniques. Comparisons between the study groups were performed using the Kruskal-Wallis test. When there were significant differences (p < 0.05), post-hoc 2-group comparisons were assessed with Bonferroni-corrected Mann-Whitney U tests, and p-values < 0.05 was considered significant. All data analysis was performed using a statistical package (Abacus Concepts Inc., Berkeley, CA, USA). The diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating characteristic (ROC) curve, and area under the ROC curve (AUC) of the test dataset were assessed. P values < 0.05 were considered statistically significant, and 95% confidence intervals (CIs) were calculated.
- Conditions
- Periodontitis, Periodontal Inflammation
- Being tested
- Peirodontal clinical measurements and gingival crevicular fluid sampling
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peirodontal clinical measurements and gingival crevicular fluid samplingOther
The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
| Study group | Role | What they receive |
|---|---|---|
| Healty group | The controls/Healthy group were the individuals with well-maintained oral hygiene without no periodontal disease history or symptoms with a probing pocket depth (PPD) of ≤3 mm and bleeding on probing (BOP) of (+) ≤10. Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling | |
| Periodontitis stage 3 grade B | Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis. These patients were graded according to the bone loss%/age index (Grade B, 0.25-1.00). Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling | |
| Periodontitis stage 3 grade C | Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis.Since the bone loss (%)/age values were >1.0, all periodontitis patients were considered grade C. Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling | |
| Gingivitis | Only generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis. Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gingival crevicular fluid Annexin-A1 levels
ng
Measured: 24 hours after clinical periodontal measurements
Gingival crevicular fluid Carbonic Anhydrase-1 levels
ng
Measured: 24 hours after clinical periodontal measurements
Gingival crevicular fluid Elongation Factor-1 Gamma- Ɣ levels
ng
Measured: 24 hours after clinical periodontal measurements
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2023
- Study start1 Sep 2022
- Primary completion1 Dec 2022
- Study completion16 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dokuz Eylul University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bilge Cansu UZUN SAYLAN, Dokuz Eylul University
- Investigators
- Bilge Cansu Uzun Saylan, Principal investigator, Dokuz Eylul UniversityVeli Özgen Öztürk, Principal investigator, Aydin Adnan Menderes UniversityHarika Atmaca İlhan, Principal investigator, Manisa Celal Bayar UniversityGülnur Emingil, Study director, Ege University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05680441
- Sponsor's protocol ID
- CANSU35
- Status last verified
- Jan 2023
- First submitted
- 26 Dec 2022
- Last updated
- 12 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Annexin-A1, Carbonic Anhydrase-1, and Elongation Factor-1 Gamma Levels in Periodontal Diseases
- ClinicalTrials.gov ID
- NCT05680441
- Acronym / sponsor ID
- CANSU35
- Conditions
- Periodontitis, Periodontal Inflammation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Dokuz Eylul UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Dec 2022 (actual)
- Study completion
- 16 Dec 2022 (actual)
- First posted
- 11 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aimed to investigate gingival crevicular fluid (GCF) levels of possible novel biomarkers Annexin-A1 (ANX A1), Carbonic anhydrase- 1 (CA I), and Elongation Factor-1 Gamma (EF1-Ɣ) in health along with different periodontal diseases.
In total, 80 systemically healthy individuals were included in this study; 20 with periodontitis stage 3 grade B , 20 with periodontitis stage 3 grade C (P-Stage III/C), 19 with gingivitis, and 21 with clinically healthy periodontium. Probing depth, clinical attachment level, plaque index, and papillary bleeding index were recorded. GCF ANX A1, CA I and EF1-Ɣ levels were analyzed by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristics curve was used for estimating the under the curve.
Detailed description
Diagnosis of periodontal diseases and conditions was arranged according to the radiographic and clinical diagnostic criteria proposed by the 2017 World Workshop on Classifcation of Periodontal and Peri-implant Diseases and Conditions; 20 patients with Stage III Grade B generalized periodontitis , 20 patients with Stage III Grade C generalized periodontitis , 19 gingivitis patients and periodontally healthy volunteers were included in this study.
The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants. The measurements were performed using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA). All measurements were performed full mouth and at 4 sites (mesio-buccal, mid-buccal, distobuccal, and mid-lingual) for each tooth. Before clinical measurements, intra-examiner calibration was performed by measuring PPD and CAL values twice on five patients with one day interval resulting in intraclass correlation coefficients were 0.92 for PD and 0.90 for CAL.
GCF samples were taken from the buccal aspects of two nonadjacent interproximal sites in single-rooted teeth. In periodontitis groups, GCF was sampled from two deepest pockets of single-rooted teeth. Samples were collected from the sites with visible signs of inflammation in gingivitis group and without BOP in the healthy group. The selected areas were carefully cleared of supragingival plaque using sterile curettes, isolated with cotton rolls, and slightly air-dried to avoid contamination.
Standardized filter paper strips (PerioPaper, Proflow, Amityville, NY) were used for GCF sampling. Sterile paper strips were gently inserted into the gingival sulcus or pocket until mild resistance was felt and left there for 30 seconds. Mechanical irritation was avoided and strips visually contaminated with blood were discarded. A precalibrated electronic device measured the absorbed fluid volume (Periotron 8010, Oraflow, Amityville, NY). The readings were converted to an actual volume (microliter, μL) by reference to the standard curve. The paper strips were individually placed into a sterile polypropylene tube and stored at -80◦C for further analysis.
Annexin-A1 levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: 201-12-3158). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the Annexin-A1 kit were 0.20-20 ng/mL, sensitivity 0.2 ng/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.
Carbonic anhydrase 1 levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: SRB-T-88927). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the CA I kit were 3.12-200ng/mL, sensitivity <1.875ng/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.
EEF1G levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: 201-12-3732). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the EF1- Ɣ kit were 31.25-2000pg/mL, sensitivity <12.4pg/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.
Statistical analysis was performed using non-parametrical techniques. Comparisons between the study groups were performed using the Kruskal-Wallis test. When there were significant differences (p < 0.05), post-hoc 2-group comparisons were assessed with Bonferroni-corrected Mann-Whitney U tests, and p-values < 0.05 was considered significant. All data analysis was performed using a statistical package (Abacus Concepts Inc., Berkeley, CA, USA). The diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating characteristic (ROC) curve, and area under the ROC curve (AUC) of the test dataset were assessed. P values < 0.05 were considered statistically significant, and 95% confidence intervals (CIs) were calculated.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Healty group | – | Other: Peirodontal clinical measurements and gingival crevicular fluid samplingThe controls/Healthy group were the individuals with well-maintained oral hygiene without no periodontal disease history or symptoms with a probing pocket depth (PPD) of ≤3 mm and bleeding on probing (BOP) of (+) ≤10. |
| Periodontitis stage 3 grade B | – | Other: Peirodontal clinical measurements and gingival crevicular fluid samplingStage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis. These patients were graded according to the bone loss%/age index (Grade B, 0.25-1.00). |
| Periodontitis stage 3 grade C | – | Other: Peirodontal clinical measurements and gingival crevicular fluid samplingStage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis.Since the bone loss (%)/age values were >1.0, all periodontitis patients were considered grade C. |
| Gingivitis | – | Other: Peirodontal clinical measurements and gingival crevicular fluid samplingOnly generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis. |
Who may qualify
- Ages
- 20 to 61 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- A total of 80 systemically healthy and non-smoker individuals(39 males, 41 females) aged 20-61 years were consecutively included.
Key inclusion criteria (2 listed)
- Non-smokers with no history of smoking(determined by self-reporting)
- Individuals who had at least 20 teeth(exclude wisdom teeth)
Key exclusion criteria (3 listed)
- Pregnant and lacting women
- Patients who under any medication including immunosuppressants, steroids, non-steroidal anti-inflammatory drugs, antibiotics, antiepileptic drugs, calcium channel blockers, beta,blockers, anticoagulants, hormonal contraceptives and nutritional supplements within 6 monthsi topical antiseptic solutions in the last 3 months.
- Patients with diagnosed medical illness such as diabetes mellitus, rheumatoid arthritis, cardiovascular diseases, immunological diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peirodontal clinical measurements and gingival crevicular fluid samplingThe clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants. | Other | Gingivitis, Healty group, Periodontitis stage 3 grade B, Periodontitis stage 3 grade C |
Primary outcome
Gingival crevicular fluid Annexin-A1 levels
Time frame: 24 hours after clinical periodontal measurements
ng
Gingival crevicular fluid Carbonic Anhydrase-1 levels
Time frame: 24 hours after clinical periodontal measurements
ng
Gingival crevicular fluid Elongation Factor-1 Gamma- Ɣ levels
Time frame: 24 hours after clinical periodontal measurements
ng
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bilge Cansu Uzun Saylan principal investigator
Dokuz Eylul University
Veli Özgen Öztürk principal investigator
Aydin Adnan Menderes University
Harika Atmaca İlhan principal investigator
Manisa Celal Bayar University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontitis and Periodontal Inflammation, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gingival crevicular fluid Annexin-A1 levels (time frame: 24 hours after clinical periodontal measurements). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2023.